ONCY Stock — Oncolytics Biotech Inc

Oncolytics Biotech Inc (ONCY)

Updated October 16, 2026.

ONCY is a Stock. Its deepest 1-year drawdown was 62.7%.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing oncology treatments, primarily pelareorep, an immunotherapeutic agent being studied for gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer, with collaborations including Roche for immune checkpoint inhibitor research. The company does not currently distribute income to shareholders. This security is suited for investors seeking exposure to early-stage cancer treatment development rather than current income.

ONCY performance

Returns are updating. ONCY's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 62.7%.

ONCY key facts

Asset type

Stock

Asset class

Equity

Inception date

10/05/2001

Distribution frequency

None

Last close

$0.50 (as of 2026-10-16)

Market cap

$65,311,230

Average volume

1333063.0

Payment date

05/25/2018

Beta

1.155

Payout ratio

0.0%

Forward P/E

45.4545

EPS

$-0.36

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ONCY risks and drawbacks

The deepest 1-year drawdown on record here is 62.7%.

Who may consider ONCY — and who may not

It is a weaker fit for investors who need monthly cash flow (ONCY does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ONCY

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions